Smith & Nephew stock gains as Deutsche Bank sticks to Hold rating
Published on 09/15/2026 at 14:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Smith & Nephew stock (ISIN GB0009223206) closed at GBX 1,048.50 on the London Stock Exchange on September 14, 2026, up 3.97 percent from the previous close as investors rotated into defensive healthcare names within the FTSE 100.
Deutsche Bank reiterates Hold with upside
According to MarketBeat on September 15, 2026, Deutsche Bank Aktiengesellschaft reiterated its Hold rating on Smith & Nephew and maintained a price target of GBX 1,250, which implies approximately 19.22 percent potential upside from the stock's recent level.
The same analyst overview reported that Smith & Nephew carries a consensus Hold rating, with three Buy recommendations and six Hold ratings, and an average target price of GBX 1,293.33, indicating that the analyst community sees some upside but remains cautious on the pace of earnings and margin improvement.
Stock outperforms FTSE 100 on healthcare strength
Per London market data compiled by Investing.com, Smith & Nephew shares traded in a range between GBX 1,026.50 and GBX 1,056.00 on September 14, 2026, before settling at the GBX 1,048.50 close, with a gain of 40.00 pence representing the 3.97 percent advance and approximately 3.14 million shares changing hands in that session.
As The Independent reported on September 14, 2026, Smith & Nephew was among the biggest risers in the FTSE 100 on that day, gaining 40.0 pence to 1,048.5 pence while the index itself rose 0.4 percent, meaning the stock’s percentage move was nearly four times the broader benchmark’s advance.
A London close summary from Sharecast on September 14, 2026 likewise highlighted Smith & Nephew at 1,048.50 pence with a 3.97 percent gain, underscoring the stock’s role among the day’s outperformers alongside other large-cap healthcare names.
Valuation signal from US-listed shares
Smith & Nephew also trades via a US listing under the symbol SNN, and valuation metrics from that venue provide additional context for investors comparing markets. According to GuruFocus on September 14, 2026, Smith & Nephew PLC shares on the US market rose 3.3 percent in that session to a price of USD 28.40, compared with a 52-week range between USD 27.23 and USD 37.78.
The same analysis cited a GF Value estimate of USD 31.34 for Smith & Nephew, placing the current USD 28.40 price 9.4 percent below that intrinsic value metric, which the outlet interprets as a margin of safety and an indication that the stock appears undervalued relative to its long-term fundamentals and historical multiples.
Price level and trading metrics
Based on the London quotation compiled by Investing.com for September 14, 2026, the GBX 1,048.50 closing price on the London Stock Exchange serves as the current reference level for Smith & Nephew stock as of the latest completed trading day, with the 40.00 pence gain reflecting a solid single-session move within the typical daily range for the shares.
Per the same London market data, the 3.97 percent rise in Smith & Nephew on September 14, 2026 outpaced the FTSE 100’s 0.4 percent advance reported by The Independent, showing that the stock not only benefited from a broadly supportive market tone but also delivered company-specific outperformance within the healthcare segment.
Closing price and investor takeaway
As of the close on September 14, 2026, Smith & Nephew stock traded at GBX 1,048.50 on the London Stock Exchange, giving investors a reference point just below Deutsche Bank’s GBX 1,250 target and the broader analyst average of GBX 1,293.33, while US-listed shares stood at USD 28.40 in their own session.
Smith & Nephew stock facts
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- Ticker: SN
- Trading venue: London Stock Exchange
- Price (as of September 14, 2026): 1,048.50 GBX
- Market capitalization: 11.49 billion GBP (as of September 15, 2026)
- Sector / Industry: Health Care Equipment & Supplies
- Index membership: FTSE 100
